16 East 34th Street floor 10
Tel: +1 510-545-3803
TrialSpark is a technology-driven drug development company that runs end-to-end clinical trials, focused on bringing new treatments to patients faster and more efficiently.
TrialSpark recently raised their Series C, and is putting the capital to work by in-licensing and co-developing drug programs through in-house development, joint ventures, and NewCos. Together with doctors, patients, and communities, TrialSpark is working to develop the treatments of tomorrow.
7 articles with TrialSpark
TrialSpark and Sanofi announced a new partnership to expedite drug development for areas with high unmet needs by licensing or acquiring six mid-to-late-stage drug candidates.
TrialSpark announces partnership with major pharmaceutical company to jointly acquire and develop clinical-stage novel therapies
TrialSpark announced a new partnership with global pharmaceutical company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently.
TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio
TrialSpark announced today the formation of High Line Bio following the acquisition of worldwide rights to sprifermin from Merck KGaA, Darmstadt, Germany.
These life sciences companies scored enough capital this week for pumpkin spice and everything nice, and to propel their candidates in the clinic. Here's a look.
This week, three global biopharmaceutical companies received over half a billion dollars to support research and development initiatives in the treatment of rare and deadly diseases.
TrialSpark's technology-enabled clinical trial platform is uniquely equipped to run challenging trials faster and more efficiently by increasing patient access to investigational medicines and dramatically expediting patient recruitment timelines
TrialSpark Inc., a tech-enabled drug development company dedicated to improving the speed, quality, and innovation of clinical trials, announces the addition of life sciences veteran Steve Holtzman as a key strategic advisor